Your browser is no longer supported. Please, upgrade your browser.
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own0.80% Shs Outstand143.34M Perf Week-7.14%
Market Cap2.33B Forward P/E11.40 EPS next Y1.43 Insider Trans4.81% Shs Float129.30M Perf Month-18.87%
Income-72.20M PEG- EPS next Q-0.02 Inst Own94.40% Short Float10.91% Perf Quarter-8.35%
Sales196.00M P/S11.88 EPS this Y10.50% Inst Trans0.23% Short Ratio7.48 Perf Half Y3.01%
Book/sh0.65 P/B25.00 EPS next Y128.16% ROA-16.20% Target Price24.20 Perf Year-3.90%
Cash/sh2.94 P/C5.53 EPS next 5Y42.00% ROE-33.70% 52W Range12.71 - 22.06 Perf YTD-8.35%
Dividend- P/FCF- EPS past 5Y2.10% ROI-13.70% 52W High-26.34% Beta1.71
Dividend %- Quick Ratio6.00 Sales past 5Y21.10% Gross Margin76.80% 52W Low27.85% ATR1.46
Employees132 Current Ratio6.30 Sales Q/Q-10.80% Oper. Margin-34.50% RSI (14)43.12 Volatility6.49% 10.30%
OptionableYes Debt/Eq4.38 EPS Q/Q- Profit Margin-36.90% Rel Volume0.37 Prev Close16.87
ShortableYes LT Debt/Eq4.17 EarningsFeb 24 AMC Payout- Avg Volume1.89M Price16.25
Recom2.40 SMA20-4.20% SMA50-13.88% SMA200-7.27% Volume704,596 Change-3.68%
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Apr-03-20 08:00AM  Halozyme Announces Change Of Location Of Annual Stockholders' Meeting PR Newswire
Mar-29-20 05:44PM  Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock? Insider Monkey
Mar-25-20 11:30AM  Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-19-20 10:30AM  Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now? Zacks +7.19%
Mar-05-20 06:36PM  Edited Transcript of HALO earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-20 08:39AM  Surging Earnings Estimates Signal Good News for Halozyme (HALO) Zacks
Feb-27-20 07:37AM  Halozyme Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-26-20 04:01PM  Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference PR Newswire
Feb-25-20 10:05AM  Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates Zacks
01:20AM  Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology PR Newswire
Feb-24-20 05:45PM  Halozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:02PM  Halozyme Reports Fourth Quarter and Full Year 2019 Results PR Newswire
04:01PM  Halozyme Announces CFO Transition PR Newswire
Feb-17-20 12:30PM  Earnings Preview: Halozyme Therapeutics (HALO) Q4 Earnings Expected to Decline Zacks
Feb-10-20 04:01PM  Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call PR Newswire
Feb-06-20 08:25AM  Is Halozyme Therapeutics (NASDAQ:HALO) Using Debt In A Risky Way? Simply Wall St.
Jan-14-20 08:00AM  Halozyme Provides 2020 Business Update And Financial Guidance PR Newswire +5.91%
Jan-03-20 08:00AM  Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-12-19 11:30AM  Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report? Zacks
02:00AM  Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium PR Newswire
Dec-06-19 10:02AM  Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Nov-20-19 05:28PM  Edited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-19 10:09AM  The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga
Nov-14-19 08:27AM  Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session Zacks
Nov-13-19 10:57PM  Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire +5.37%
09:06AM  Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3 Zacks
Nov-12-19 05:45PM  Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:30PM  Bernadette Connaughton Appointed to Syneos Health Board of Directors GlobeNewswire
04:10PM  Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire
04:01PM  Halozyme Reports Third Quarter 2019 Results PR Newswire
Nov-07-19 12:56PM  Long-Term Signal Says Buy This Biotech Schaeffer's Investment Research
Nov-05-19 10:32AM  Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +10.46%
Nov-04-19 09:56AM  Halozyme Scraps Oncology Program Following Failed Study, Charts Out Profitability Plan Benzinga
07:00AM  Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint PR Newswire
07:00AM  Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology PR Newswire
Nov-01-19 09:05AM  Do Institutions Own Shares In Halozyme Therapeutics, Inc. (NASDAQ:HALO)? Simply Wall St.
Oct-23-19 01:30PM  is Halozyme Therapeutics, Inc. (HALO) Going To Burn These Hedge Funds? Insider Monkey
Oct-21-19 08:00AM  Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call PR Newswire
Oct-02-19 09:14AM  How Many Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
Sep-23-19 08:00AM  Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire
Sep-13-19 09:44PM  Edited Transcript of HALO earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
05:27PM  Roche's New Perjeta Combo Meets Goal in Breast Cancer Study Zacks
01:00AM  Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology PR Newswire
Sep-02-19 10:48AM  Why Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) CEO Pay Matters To You Simply Wall St.
Aug-26-19 08:00AM  Halozyme To Participate In 2019 Wells Fargo Healthcare Conference PR Newswire
Aug-08-19 10:58AM  Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:15PM  Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Halozyme Reports Second Quarter 2019 Results PR Newswire
12:20PM  Is Halozyme Therapeutics (NASDAQ:HALO) Weighed On By Its Debt Load? Simply Wall St.
Jul-30-19 10:38AM  Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline Zacks
Jul-25-19 08:00AM  Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference PR Newswire
Jul-23-19 04:01PM  Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire
Jul-22-19 10:16AM  Alexion (ALXN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-19-19 07:00AM  Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire
Jul-17-19 08:00AM  Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology PR Newswire
Jul-12-19 11:59AM  Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire
Jul-04-19 01:44PM  The Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Gained 99% And Shareholders Are Hoping For More Simply Wall St.
Jun-25-19 08:00AM  Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology PR Newswire
Jun-12-19 05:04PM  Edited Transcript of HALO earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 04:37PM  Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy? Insider Monkey
Jun-04-19 08:00AM  Halozyme To Participate In Upcoming Investor Conferences PR Newswire
Jun-03-19 01:34PM  Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-22-19 01:05AM  Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire
May-21-19 07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-13-19 08:01AM  Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
May-07-19 09:23PM  Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript Motley Fool
06:05PM  Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates Zacks
05:01PM  Halozyme Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Halozyme Reports First Quarter 2019 Results PR Newswire
02:30AM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-19 08:00AM  Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire
May-01-19 10:29AM  How Halozyme Therapeutics, Inc. (NASDAQ:HALO) Can Impact Your Portfolio Volatility Simply Wall St.
Apr-30-19 03:14PM  Heres What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Anymore Insider Monkey
10:32AM  Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? Zacks
07:00AM  REPEAT/Halo Labs Begins Trading on the OTCQX Market Business Wire
03:00AM  Halo Labs Begins Trading on the OTCQX Market Business Wire
Apr-23-19 04:01PM  Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call PR Newswire
Apr-02-19 11:36AM  Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares Simply Wall St.
Mar-23-19 12:14PM  3 Cancer Treatment Stocks to Buy in March Motley Fool
Mar-11-19 07:43PM  Avid Bioservices, Inc. (CDMO) Q3 2019 Earnings Conference Call Transcript Motley Fool
Mar-10-19 10:45AM  2 Stocks You Definitely Should Consider Shorting This Week TheStreet.com
Mar-08-19 09:58AM  Halo Labs Announces Hush and Gilt Product Lines to Be Distributed by C4 Distro in Southern California Business Wire
01:19AM  Halo Labs Announces Hush and Gilt Product Lines to Be Distributed by C4 Distro in Southern California Business Wire
Mar-07-19 10:08AM  Halo Labs Announces Short Form Prospectus Offering of Convertible Debenture Units Business Wire
Mar-05-19 04:01PM  Halo Labs Awarded Annual Cannabis Manufacturing License by California, among the First to Implement Track and Trace (METRC) Business Wire
Mar-04-19 09:54AM  Top Ranked Momentum Stocks to Buy for March 4th Zacks
08:01AM  Halozyme To Participate In Upcoming Investor Conferences PR Newswire
Mar-01-19 04:33PM  Halo Labs Reports Record Monthly Revenue of Approximately US$2.6 Million (CDN $3.4 Million) In the Shortened Month of February Business Wire
06:25AM  Edited Transcript of HALO earnings conference call or presentation 21-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:47AM  Halozyme Announces FDA Approval Of Herceptin Hylecta PR Newswire
Feb-26-19 04:01PM  Halo Labs Successfully Launches DabTabs in Oregon and Nevada Business Wire
Feb-25-19 04:42PM  Halo Labs Signs Bulk Biomass Procurement and Bulk Extract Supply Agreement with Cannus Partners in California Business Wire
06:00AM  Halo Labs to Present at The Gravitas Growth Conference in Vancouver Business Wire
Feb-22-19 08:00AM  REPEAT/Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF Business Wire
Feb-21-19 10:09PM  Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:15PM  Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:20PM  Halozyme Therapeutics: 4Q Earnings Snapshot Associated Press
04:32PM  Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF Business Wire
04:01PM  Halozyme Reports Fourth Quarter And Full-Year 2018 Results PR Newswire
07:32AM  The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan Benzinga
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelley Kenneth JDirectorMar 19Buy14.2352,629748,697277,553Mar 19 07:28 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030179,231Feb 24 08:04 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,3920120,675Feb 24 08:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540510,033Feb 24 08:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7720172,423Feb 18 04:16 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,8090111,983Feb 18 04:15 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300484,923Feb 18 04:14 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,13008,619Feb 13 06:41 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,376Feb 13 06:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 12Option Exercise0.0011,2620108,068Feb 13 06:38 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950472,452Feb 13 06:24 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 03Option Exercise0.0011,5590165,782Feb 04 04:24 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,1190105,081Feb 04 04:21 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870459,567Feb 04 04:18 PM
Hickey BenjaminSVP, Chief Commerical OfficerOct 01Option Exercise0.0020,216020,216Oct 01 07:10 PM
Chondros DimitriosSVP, Chief Medical OfficerAug 03Sale16.701,32822,17838,584Aug 05 08:11 PM
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875085,370Jun 17 08:19 AM
Chondros DimitriosSVP, Chief Medical OfficerJun 01Option Exercise0.002,043040,618Jun 03 05:22 PM
LEONHARDT HARRY JSVP, GCApr 13Option Exercise0.006,875068,750Apr 15 04:08 PM